Leqvio Dosing: 284 mg Schedule and No Titration Needed

Updated May 27, 2026

Image: HealthRX.com clinical image

Pending qualified clinical review. This article has not yet been confirmed by a licensed prescriber and should not be used alone to make a dosing decision. Several precise figures below need verification against the current FDA label before publication.

Inclisiran, sold as Leqvio, is a small interfering RNA (siRNA) therapy that lowers LDL cholesterol by silencing hepatic production of PCSK9. It is not a monoclonal antibody like evolocumab (Repatha) or alirocumab (Praluent), and it is not a statin. It is FDA-approved as an adjunct to diet and maximally tolerated statin therapy for adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL-C lowering.

The direct answer

Inclisiran has one FDA-approved dose: 284 mg by subcutaneous injection, given by a healthcare professional, with no titration ladder and no higher-dose option. The approved schedule is an injection at day 0, a second injection at day 90, then one injection every six months thereafter (FDA prescribing information). If LDL-C remains above goal after the two loading doses and steady state is reached, the evidence-based next step is not a higher inclisiran dose, because none exists, but adding or optimizing other lipid-lowering agents (statin intensity, ezetimibe, or bempedoic acid) under clinician guidance.

Why there is no dose escalation

Statins and ezetimibe work through direct, dose-dependent enzyme or transporter inhibition, so raising the dose can raise the effect, at least up to a ceiling. Inclisiran works differently. After subcutaneous injection, its GalNAc conjugate directs uptake into hepatocytes, where the drug loads into the RNA-induced silencing complex (RISC) and catalytically degrades PCSK9 messenger RNA. Because one loaded RISC complex can process many mRNA copies, the dose-response relationship flattens out well below doses that would be toxic or impractical. Early phase 2 dose-ranging work reportedly tested a range of doses and dosing intervals and found that pushing higher than the eventual approved regimen did not produce proportionally greater or more durable LDL-C lowering. The specific percentages from that dose-ranging study are not independently verified in this draft and should be confirmed against the primary publication before being cited with precision.

The practical result is a plateau: at the approved 284 mg dose, PCSK9 suppression is already close to the ceiling the drug can achieve, and manufacturer and regulators settled on a single fixed dose rather than a titration schedule. This is a pharmacologic ceiling, not an oversight, and it is the reason "increasing" inclisiran is not a real clinical option in the way increasing a statin dose is.

The approved dosing schedule

Day 0 (first loading dose). A 284 mg injection is given in a clinical setting. PCSK9 suppression begins quickly, but the full LDL-C effect develops over roughly two to three months, not days.

Day 90 (second loading dose). A second 284 mg injection consolidates the effect and is what pushes the regimen to its expected steady-state LDL-C reduction. Skipping or substantially delaying this dose is expected to blunt and delay the full effect, though the size of that blunting in any individual patient cannot be predicted from label data alone.

Every six months thereafter. Maintenance dosing is twice yearly, all in-office. There is no self-injection option and no home administration on the current label.

A baseline fasting lipid panel before the first injection, and a follow-up panel around 90 days after an injection, are reasonable ways to track response, aligned with the injection schedule. The exact monitoring cadence should be set by the treating clinician rather than derived from this article.

What the pivotal trials showed, and what needs verification

Inclisiran's approval rested on phase 3 trials (commonly referenced under the ORION program name) in patients with ASCVD or HeFH already on maximally tolerated statin therapy. These trials, together with the FDA label, describe roughly a 50 percent reduction in LDL-C from baseline compared with placebo, sustained through the dosing interval. That approximate figure is consistent with the FDA label and is reasonable to state as an evidence-anchored range. More granular numbers occasionally cited elsewhere, such as reductions carried to a decimal point or broken out by exact trial arm, should be checked against the original journal publications before being reused, because this draft could not independently verify each figure inherited from prior source material.

Reported adverse events in the pivotal program were dominated by mild, self-limited injection-site reactions, with no clear signal for liver injury, muscle toxicity, or cognitive effects at the population level. A dedicated cardiovascular outcomes trial for inclisiran (commonly referred to as ORION-4) has been designed to test whether LDL-C lowering with inclisiran translates into fewer cardiovascular events; as of this writing that trial's primary results have not been confirmed in this draft and should not be assumed. Current approval rests on LDL-C as a validated surrogate endpoint, not on a completed outcomes trial for inclisiran itself. This distinction matters: unlike evolocumab and alirocumab, which have their own completed cardiovascular outcomes trials, inclisiran's cardiovascular benefit is inferred rather than directly demonstrated at this time.

The following short passage summarizes what is established:

Inclisiran (Leqvio) has a single FDA-approved dose of 284 mg subcutaneous injection, given at day 0, day 90, and then every six months, with no titration option in either direction. Its approximate 50 percent LDL-C reduction is supported by the pivotal phase 3 program and reflected in the FDA label, but a dedicated cardiovascular outcomes trial for inclisiran has not yet reported confirmed results, so its outcome benefit beyond LDL-C lowering is inferred rather than directly proven as of this review.

When LDL-C stays above goal on inclisiran alone

This is a common and expected scenario, not a treatment failure requiring dose escalation, because escalation is not possible. Guideline bodies such as the ACC/AHA and ESC/EAS set LDL-C targets that vary by risk category, with more aggressive targets for very high-risk ASCVD patients. Reasonable next steps, all of which require individualized clinical judgment rather than a fixed algorithm, include:

Confirming the patient is on the highest statin dose they can tolerate, since statins and inclisiran act on different points of the same pathway (synthesis versus receptor degradation) and their effects are broadly additive.
Adding ezetimibe, which blocks intestinal cholesterol absorption and is well established as an add-on to statin therapy.
Considering bempedoic acid for patients who are statin-intolerant or still above goal on combination therapy; bempedoic acid has its own completed cardiovascular outcomes trial in statin-intolerant patients, distinct from inclisiran's evidence base.
Reassessing whether a PCSK9 monoclonal antibody (evolocumab or alirocumab) might be more appropriate for a patient who needs a demonstrated cardiovascular outcomes benefit now rather than an inferred one.

None of this substitutes for a conversation with the prescribing clinician about the patient's specific risk category, comorbidities, and prior response.

Inclisiran versus PCSK9 monoclonal antibodies: what is actually known

Inclisiran, evolocumab, and alirocumab all target the PCSK9 pathway, but through different mechanisms and schedules: inclisiran silences PCSK9 production inside liver cells via siRNA, while the antibodies neutralize circulating PCSK9 protein. Evolocumab and alirocumab require self-injection every two to four weeks; inclisiran is given in-office twice yearly after loading. No completed head-to-head randomized trial has directly compared inclisiran to either antibody, so any comparison of effect sizes across separate trials is indirect and subject to differences in trial populations. The clearest documented difference is administration burden and frequency, not proven superiority of one drug's cardiovascular benefit over another, since only evolocumab and alirocumab currently have completed outcomes trials of their own.

Missed doses: what the label says versus what is individualized

The general framework on the current label is that a modestly late second loading dose or maintenance dose can typically be given as soon as convenient with the schedule resuming from that point, while a maintenance dose delayed well beyond the six-month interval may warrant restarting the full loading sequence. The exact day thresholds in the label should be confirmed directly with the current prescribing information or the treating clinic, since these details are the kind of precise, volatile fact that this draft cannot fully verify from the source material provided. This is squarely a "check the label and call the clinic" situation, not one to manage from a general article.

Special populations and open questions

Renal impairment: The label reportedly does not require dose adjustment in mild to moderate renal impairment, based on a small pharmacokinetic study. Data in severe renal impairment are limited, and this population needs individualized clinician judgment rather than reliance on a general summary.
Hepatic impairment: Patients with significant liver disease were largely excluded from the pivotal trials, so evidence in this group is limited.
Lipoprotein(a): Inclisiran has been reported to lower Lp(a) as a secondary effect in pooled trial data, but there is no dedicated Lp(a) outcomes trial for inclisiran, and this should be treated as an observed association rather than a proven clinical benefit for Lp(a)-specific risk reduction.
Next-generation siRNA agents: Longer-acting PCSK9-targeting or Lp(a)-targeting siRNA molecules are reportedly in earlier-stage development at other companies. Details of trial design and results were not independently verified for this draft and should not be cited as established until confirmed against primary sources.

Cost and coverage: what changes over time

Inclisiran is billed as a physician-administered drug, which generally places it under Medicare Part B rather than Part D, a structural distinction that is well established for provider-administered biologics in general. Specific dollar figures for wholesale acquisition cost, typical coinsurance amounts, and manufacturer copay assistance change over time and were not independently verified for this draft. Anyone making a coverage or cost decision should confirm current pricing and prior authorization requirements directly with their insurer, pharmacy benefit, or the manufacturer's patient support program rather than relying on figures in an educational article.

Clinician conversation and monitoring framework

This framework is meant to support a conversation with a prescriber, not to replace one. It distinguishes what is fixed by the label from what depends on individual judgment.

Before the first injection (label-defined)

Confirm the indication: established ASCVD or HeFH, on maximally tolerated statin therapy where appropriate.
Baseline fasting lipid panel.
Confirm the drug will be administered by a healthcare professional; no home self-injection is approved.

Day 90 checkpoint (label-defined, with individualized follow-up)

Second 284 mg injection due.
Consider a lipid panel around this point to see early response, understanding the full nadir may take longer.
Escalation trigger for clinician discussion, not self-management: if the second dose is delayed, ask the clinic directly how the label's missed-dose guidance applies, rather than assuming a fixed rule from this article.

Around day 180 and every 6 months after (label-defined schedule, individualized target)

Maintenance 284 mg injection.
Fasting lipid panel to assess whether the patient's individualized LDL-C target (set by the clinician using guideline risk categories) has been met.
If LDL-C is at goal: continue the twice-yearly schedule and routine follow-up.
If LDL-C is above goal: this is not a dose problem. The clinician-led decision point is whether to intensify the statin, add ezetimibe, add bempedoic acid, or reconsider a PCSK9 monoclonal antibody, weighed against the patient's tolerance, adherence pattern, and risk category.

Stop or escalate to urgent evaluation (individualized, not routine)

New or worsening muscle pain, jaundice, dark urine, or signs of a significant allergic reaction after injection should prompt contact with the prescriber or urgent care rather than waiting for the next scheduled visit.
Persistent or worsening injection-site reactions beyond mild, self-limited redness or swelling warrant a call to the prescribing clinic.

Outside the label's scope (requires individualized judgment)

Severe renal or hepatic impairment.
Pregnancy or lactation, where trial data are limited.
Any request to increase the dose or shorten the interval below what the label specifies, which is not supported by current evidence and should not be pursued outside a clinical trial.

Questions this article can and cannot answer

Can the inclisiran dose be increased if LDL-C is still too high? No. The FDA-approved dose is fixed at 284 mg; there is no higher approved dose, and any residual LDL-C gap is addressed by adding other therapies, not by giving more inclisiran.

Is inclisiran interchangeable with evolocumab or alirocumab? They act on the same pathway but differently, and no completed head-to-head trial has compared them directly. Choice between them depends on adherence pattern, needle preference, insurance coverage, and whether a completed cardiovascular outcomes trial for the specific drug matters to the patient's care team.

Does missing a dose ruin the treatment? A short delay is generally recoverable under label guidance, but the exact thresholds for restarting the loading sequence should be confirmed with the current label and the prescribing clinic rather than assumed from this summary.

Has inclisiran been proven to reduce heart attacks and strokes, not just LDL-C? Not yet confirmed in this draft. Approval is based on LDL-C as a surrogate endpoint, and a dedicated cardiovascular outcomes trial for inclisiran has not been verified here as completed or reported.

References and further reading

Specific trial percentages, quotations, and pricing figures vary between sources and have not been independently confirmed here; readers should consult the current FDA label and the original ORION trial publications for precise figures.